Quantumzyme Corp., a biotechnology company specializing in enzyme-driven green chemistry solutions, has entered into a Memorandum of Understanding with artificial intelligence and data science company Predictive Research Inc. The agreement establishes a framework to evaluate potential collaboration at the intersection of artificial intelligence, biocatalysis, and sustainable chemical innovation. The MoU outlines plans to assess how advanced artificial intelligence, machine learning, and data-driven methodologies could support research and development in enzyme engineering, green chemistry, and related pharmaceutical and industrial processes.
Quantumzyme employs quantum mechanics-informed modeling, molecular simulation, and computational design through its proprietary QZyme Workbench™ platform to optimize enzyme activity, selectivity, and stability for applications across pharmaceuticals, specialty chemicals, fragrances, food ingredients, and textiles. Predictive Research brings expertise in generative artificial intelligence, natural language processing, machine learning, and advanced analytics from sectors including healthcare, life sciences, finance, retail, telecommunications, and automotive. The collaboration will explore AI-supported approaches to enzyme engineering, data-driven methodologies for sustainable biotransformation concepts, AI-enabled insights from complex biological and chemical datasets, and structured knowledge sharing between scientific and data science teams.
"This MoU reflects our interest in evaluating how advanced AI and data-driven approaches may complement our computational enzyme engineering platform," said Naveen Krishnarao Kulkarni, Chief Executive Officer of Quantumzyme Corp. "While still at an exploratory stage, collaborations such as this may help inform future research directions as we continue to pursue more sustainable solutions in green chemistry." Dr. Basavaraj S. Patil, Chief Data Scientist at Predictive Research Inc., added, "We view this MoU as an opportunity to explore how generative AI and predictive analytics could be applied within complex biochemical and catalytic research environments. By combining complementary technical perspectives, both organizations aim to assess new approaches to data-informed innovation in life sciences."
The partnership represents a convergence of biotechnology and artificial intelligence aimed at developing more sustainable alternatives to conventional chemical processes. Biocatalysts developed through such collaborations could offer pathways to reduced environmental impact and improved process efficiency across multiple industries. For more information, visit https://www.quantumzymecorp.com and the company's profile at https://www.otcmarkets.com/stock/QTZM.
